Want to see HK:2373 full AI Analyst Report?
2373 Stock Chart & Stats
HK$26.36
HK$0.14(0.75%)
At close: 4:00 PM EST
HK$26.36
HK$0.14(0.75%)
Day’s Range― - ―
52-Week RangeHK$15.60 - HK$41.60
Previous CloseN/A
Volume52.00K
Average Volume (3M)539.77K
Market Cap
HK$4.27B
Enterprise ValueHK$4.04B
Total Cash (Recent Filing)HK$2.57B
Total Debt (Recent Filing)HK$1.29B
Price to Earnings (P/E)10.0
Beta0.48
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.97%
Share Statistics
EPS (TTM)1.38
Shares Outstanding251,593,720
10 Day Avg. Volume911,428
30 Day Avg. Volume539,766
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)5.54
Price to Sales (P/S)1.89
P/FCF Ratio6.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$28.00Price Target Upside6.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.79
Revenue Forecast (FY)HK$3.99B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsThe company delivered a marked step-up in revenue in 2025 alongside improving net and gross margins. Sustained top-line expansion with rising profitability supports durable cash generation and reinvestment capacity, underpinning medium-term earnings resilience and strategic flexibility.
Cash GenerationOperating and free cash flow increases in 2025 indicate solid cash conversion from core operations. Reliable cash generation strengthens the company’s ability to fund capex, service debt, and support distributions, providing a durable funding base for growth and financial stability.
Equity Base & ReturnsA meaningful equity base combined with strong ROE gives the firm a resilient capital foundation. This supports absorbing shocks, financing expansion without excessive dilution, and sustaining returning capital to shareholders, all of which favor long-term financial flexibility.
Bears Say
Rising LeverageLeverage jumped materially in 2025, raising financial risk and reducing balance sheet flexibility. Higher debt levels increase interest exposure and constrain capacity for opportunistic investments or downturn mitigation, making the company more sensitive to macro shocks and cash-flow variability.
Cash Flow Quality UncertaintyDespite reported increases in operating cash, negative free cash flow growth and zeroed coverage metrics in 2025 create ambiguity around cash quality and comparability. This undermines confidence in sustainable cash available for deleveraging, dividends, or reinvestment over the medium term.
Margin & Earnings VolatilityHistorical margin swings and a prior revenue decline point to less predictable earnings generation. Volatility in EBITDA and revenue history suggests sensitivity to demand cycles or operational factors, reducing forecast reliability and complicating long-term planning for margins and capital allocation.
Beauty Farm Medical & Health Industry, Inc. News
2373 FAQ
What was Beauty Farm Medical & Health Industry, Inc.’s price range in the past 12 months?
Beauty Farm Medical & Health Industry, Inc. lowest stock price was HK$15.60 and its highest was HK$41.60 in the past 12 months.
What is Beauty Farm Medical & Health Industry, Inc.’s market cap?
Beauty Farm Medical & Health Industry, Inc.’s market cap is HK$4.27B.
When is Beauty Farm Medical & Health Industry, Inc.’s upcoming earnings report date?
Beauty Farm Medical & Health Industry, Inc.’s upcoming earnings report date is Sep 01, 2026 which is in 59 days.
How were Beauty Farm Medical & Health Industry, Inc.’s earnings last quarter?
Beauty Farm Medical & Health Industry, Inc. released its earnings results on Mar 27, 2026. The company reported HK$0.752 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.752.
Is Beauty Farm Medical & Health Industry, Inc. overvalued?
According to Wall Street analysts Beauty Farm Medical & Health Industry, Inc.’s price is currently Undervalued.
Does Beauty Farm Medical & Health Industry, Inc. pay dividends?
Beauty Farm Medical & Health Industry, Inc. pays a Annually dividend of HK$0.72 which represents an annual dividend yield of 1.97%. See more information on Beauty Farm Medical & Health Industry, Inc. dividends here
What is Beauty Farm Medical & Health Industry, Inc.’s EPS estimate?
Beauty Farm Medical & Health Industry, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beauty Farm Medical & Health Industry, Inc. have?
Beauty Farm Medical & Health Industry, Inc. has 251,593,720 shares outstanding.
What happened to Beauty Farm Medical & Health Industry, Inc.’s price movement after its last earnings report?
Beauty Farm Medical & Health Industry, Inc. reported an EPS of HK$0.752 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.147%.
Which hedge fund is a major shareholder of Beauty Farm Medical & Health Industry, Inc.?
Currently, no hedge funds are holding shares in HK:2373
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beauty Farm Medical & Health Industry, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.26%
12-Months-Change
Fundamentals
Return on Equity
33.37%
Trailing 12-Months
Asset Growth
23.50%
Trailing 12-Months
Company Description
Beauty Farm Medical & Health Industry, Inc.
Beauty Farm Medical and Health Industry Inc., established in 1993 and based in Shanghai, People's Republic of China, delivers comprehensive beauty and health management services across China. Its diverse offerings encompass traditional beauty treatments; advanced aesthetic medical services, including non-surgical options like energy-based therapies and injections, as well as surgical procedures; and specialized subhealth assessment and intervention programs. As of June 30, 2022, the company operated a network of 352 stores under its BeautyFarm, Palaispa, Neology, and CellCare brands, with 177 being directly owned and 175 franchised.
2373 Stock 12 Month Forecast
Average Price Target
HK$28.00
▲(6.22% Upside)
Technical Analysis
Raily Aesthetic Medicine International Holdings Limited
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Arrail Group Ltd.
―
UMP Healthcare Holdings Limited
―
Options Prices
Currently, No data available
---